Shots:

• The first patient has been dosed in a P-I study of HLX14- conducted in 2 parts- Part 1 is a pilot study assessing PK/PD- safety- tolerability & immunogenicity of HLX14 vs EU-sourced denosumab (SC) in healthy male volunteers
• Part 2 is a four-arm study assessing the bioequivalence of HLX14 vs US-- EU-- CN-sourced denosumab. The study also evaluates PD- safety- tolerability- and immunogenicity between HLX14 and the reference drug
• Results from the P-I study will provide reference for the dosing scheme in the clinical studies of HLX14

 ­ Ref: Henlius | Image: BioSpectrum Asia